Real-World Economic Impact of OnabotulinumtoxinA in Patients with Chronic Migraine

被引：0
|
作者：
Rothrock, John [1 ]
Bloudek, Lisa [2 ]
Houle, Timothy [3 ]
Andress-Rothrock, Diane [4 ]
Hanlon, Christopher [1 ]
Varon, Sepideh [2 ]
机构：
[1] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA
[2] Allergan, Irvine, CA USA
[3] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA
[4] Univ Alabama Birmingham, Headache Treatment & Res Program, Birmingham, AL USA
来源：
NEUROLOGY | 2012年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P03233
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A single-center retrospective study of onabotulinumtoxinA for treatment of 245 chronic migraine patients: survey results of a real-world experience
    Pınar Yalinay Dikmen
    Seda Kosak
    Elif Ilgaz Aydinlar
    Ayse Sagduyu Kocaman
    Acta Neurologica Belgica, 2018, 118 : 475 - 484
  • [22] Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or CGRP mAbs: A retrospective claims analysis study
    Schwedt, T. J.
    Lee, J.
    Knievel, K.
    McVige, J. W.
    Wang, W.
    Wu, Z.
    Gillard, P.
    Shah, D.
    Blumenfeld, A. M.
    HEADACHE, 2022, 62 : 81 - 82
  • [23] REAL-WORLD EVIDENCE FOR CONTROL OF PATIENTS WITH CHRONIC MIGRAINE WHO RECEIVED CGRP MONOCLONAL ANTIBODY THERAPY ADDED TO ONABOTULINUMTOXINA TREATMENT
    Blumenfeld, Andrew M.
    Frishberg, Benjamin M.
    Schim, Jack D.
    Iannone, Ashley
    Schneider, Gary
    Yedigarova, Larisa
    Adams, Aubrey Manack
    CEPHALALGIA, 2020, 40 : 96 - 97
  • [24] Real-World Persistence and Costs Among Patients With Chronic Migraine Treated With OnabotulinumtoxinA or CGRP mAbs: A Retrospective Claims Analysis Study
    Schwedt, Todd J.
    Lee, Jae
    Knievel, Kerry
    McVige, Jennifer
    Wang, Weiying
    Wu, Zheng
    Gillard, Patrick
    Shah, Darshini
    Blumenfeld, Andrew M.
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 18 - 19
  • [25] A single-center retrospective study of onabotulinumtoxinA for treatment of 245 chronic migraine patients: survey results of a real-world experience
    Dikmen, Pinar Yalinay
    Kosak, Seda
    Aydinlar, Elif Ilgaz
    Kocaman, Ayse Sagduyu
    ACTA NEUROLOGICA BELGICA, 2018, 118 (03) : 475 - 484
  • [26] Real-World Persistence and Costs Among Patients With Chronic Migraine Treated With OnabotulinumtoxinA or CGRP mAbs: A Retrospective Claims Analysis Study
    Schwedt, T.
    Lee, J.
    Knievel, K.
    McVige, J.
    Wang, W.
    Wu, Z.
    Gillard, P.
    Shah, D.
    Blumenfeld, A.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [27] Real-world treatment chronic migraine in Poland
    Domitrz, Izabela
    Karaszewski, Bartosz
    Stepien, Adam
    ARCHIVES OF MEDICAL SCIENCE, 2024, 20 (06) : 2082 - 2084
  • [28] Real-world treatment utilisation and safety of onabotulinumtoxinA for chronic migraine: results from an observational study in the European Union
    Matharu, M.
    Pascual, J.
    Nilsson-Remahl, I.
    Straube, A.
    Lum, A.
    Davar, G.
    Odom, D.
    Bennett, L.
    Proctor, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 115 - 115
  • [29] Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
    Taoufik Alsaadi
    Suzan Noori
    Razmig Varakian
    Saly Youssef
    AbuBaker Almadani
    BMC Neurology, 22
  • [30] Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
    Alsaadi, Taoufik
    Noori, Suzan
    Varakian, Razmig
    Youssef, Saly
    Almadani, AbuBaker
    BMC NEUROLOGY, 2022, 22 (01)
12345